Stryker (NYSE:SYK) will announce its earnings results after the market closes on Thursday, October 25th. Analysts expect the company to announce earnings of $1.68 per share for the quarter. Stryker has set its Q3 guidance at $1.65-1.70 EPS and its FY18 guidance at $7.22-7.27 EPS.
Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, July 24th. The medical technology company reported $1.76 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.73 by $0.03. The business had revenue of $3.32 billion during the quarter, compared to the consensus estimate of $3.31 billion. Stryker had a return on equity of 26.93% and a net margin of 8.28%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company posted $1.53 EPS. On average, analysts expect Stryker to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.
Stryker stock opened at $176.23 on Thursday. The stock has a market cap of $66.45 billion, a price-to-earnings ratio of 27.15, a PEG ratio of 2.49 and a beta of 0.59. Stryker has a 52-week low of $146.80 and a 52-week high of $179.84. The company has a quick ratio of 1.15, a current ratio of 1.83 and a debt-to-equity ratio of 0.63.
In related news, VP Katherine Ann Owen sold 37,866 shares of the business’s stock in a transaction that occurred on Wednesday, September 5th. The stock was sold at an average price of $166.84, for a total value of $6,317,563.44. Following the transaction, the vice president now directly owns 11,367 shares of the company’s stock, valued at approximately $1,896,470.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Glenn S. Boehnlein sold 750 shares of the business’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $178.17, for a total value of $133,627.50. Following the completion of the transaction, the chief financial officer now directly owns 2,785 shares in the company, valued at $496,203.45. The disclosure for this sale can be found here. Insiders own 7.30% of the company’s stock.
A number of equities research analysts have issued reports on SYK shares. JPMorgan Chase & Co. boosted their price target on Stryker to $200.00 and gave the company an “overweight” rating in a research note on Thursday, September 13th. Zacks Investment Research downgraded Stryker from a “buy” rating to a “hold” rating in a research note on Wednesday, August 8th. Barclays started coverage on Stryker in a research note on Monday. They set an “overweight” rating and a $198.00 price target for the company. Robert W. Baird boosted their price target on Stryker from $187.00 to $192.00 and gave the company an “outperform” rating in a research note on Wednesday, July 25th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Stryker in a research note on Tuesday, September 11th. Eight analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $180.71.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.